An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer

[1]  G. Ball,et al.  The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer , 2010, Breast Cancer Research and Treatment.

[2]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Merino,et al.  FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. , 2008, Blood.

[4]  K. Allison,et al.  Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target , 2008, Modern Pathology.

[5]  I. Ellis,et al.  Expression of BRCA1 protein in breast cancer and its prognostic significance. , 2008, Human pathology.

[6]  I. Frydecka,et al.  The significance of Treg cells in defective tumor immunity , 2008, Archivum Immunologiae et Therapiae Experimentalis.

[7]  B. Chauffert,et al.  Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.

[8]  S. Kondo,et al.  Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma , 2008, British Journal of Cancer.

[9]  I. Ellis,et al.  The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome , 2008, Breast Cancer Research and Treatment.

[10]  K. Gourgoulianis,et al.  Foxp3 expression in human cancer cells , 2008, Journal of Translational Medicine.

[11]  S. Dermime,et al.  FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy , 2008, BMC Cancer.

[12]  C. Pilarsky,et al.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. , 2007, Cancer research.

[13]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[15]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[16]  M. Joshi,et al.  Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients , 2006, Cancer.

[17]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Douglas Macmillan,et al.  Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. , 2006, European journal of cancer.

[19]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[20]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[21]  G. Grabenbauer,et al.  Tumor-Infiltrating Cytotoxic T Cells but not Regulatory T Cells Predict Outcome in Anal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[22]  David L Rimm,et al.  Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. , 2006, Cancer research.

[23]  I. Fentiman,et al.  Different patterns of inflammation and prognosis in invasive carcinoma of the breast , 2006, Histopathology.

[24]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[25]  yang-xin fu,et al.  Tumor-infiltrating T lymphocytes: friends or foes? , 2006, Laboratory Investigation.

[26]  E. Tartour,et al.  Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers , 2006, Clinical Cancer Research.

[27]  H. Stein,et al.  Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. , 2006, European journal of immunology.

[28]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Fiegl,et al.  The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer , 2005, Clinical Cancer Research.

[30]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[31]  Fiona Powrie,et al.  Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single‐cell level , 2005, European journal of immunology.

[32]  A. Rudensky,et al.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3. , 2005, Immunity.

[33]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[34]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[35]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[36]  S. Ziegler,et al.  Regulating the immune system: the induction of regulatory T cells in the periphery , 2004, Arthritis research & therapy.

[37]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[38]  F. Ramsdell,et al.  Foxp3 and natural regulatory T cells: key to a cell lineage? , 2003, Immunity.

[39]  J. Sprent,et al.  Knowing one's self: central tolerance revisited , 2003, Nature Immunology.

[40]  Carlos Caldas,et al.  Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[41]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[43]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[44]  Hiroshi Tanaka,et al.  Depletion of CD4+CD25+ Regulatory Cells Augments the Generation of Specific Immune T Cells in Tumor-Draining Lymph Nodes , 2002, Journal of immunotherapy.

[45]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[46]  G. Schuler,et al.  Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.

[47]  S. Sakaguchi.  Regulatory T cells , 2000, Cell.

[48]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[49]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[50]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[51]  G. Heppner,et al.  Immunological enhancement of breast cancer , 1997, Parasitology.

[52]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[53]  C. Gallo,et al.  Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. , 1995, Oncology.

[54]  S. Pinder,et al.  Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.

[55]  R. Blamey,et al.  Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐up , 1992, Histopathology.

[56]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[57]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.